| AML | acute myeloid leukaemia |
| ALBI | albumin–bilirubin |
| AFP | alpha fetoprotein |
| ADA | anti-drug antibody |
| ABC | ATP-binding cassette |
| CSC | cancer stem cell |
| CAF | cancer-associated fibroblast |
| CAR | chimeric antigen receptor |
| CTC | circulating tumour cell |
| ctDNA | circulating tumour DNA |
| CDK | cyclin-dependent kinase |
| CTLA-4 | cytotoxic T-lymphocyte-associated protein 4 |
| DNMT | DNA methyltransferase |
| DOR | duration of response |
| EGFR | epidermal growth factor receptor |
| EMT | epithelial–mesenchymal transition |
| ECM | extracellular matrix |
| EZH2 | enhancer of zeste homolog 2 |
| FGFR | fibroblast growth factor receptor |
| Foxp3+ Tregs | forkhead box P3 regulatory T cells |
| Gd-EOB-DTPA | gadolinium-ethoxybenzyl-diethylenetriamine |
| GPC-3 | Glypican-3 |
| HR | hazard ratio |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HCC | hepatocellular carcinoma |
| HGF | hepatocyte growth factor |
| HAT | histone acetyltransferase |
| HDAC | histone deacetylase |
| HIF-α | hypoxia-inducible factor-α |
| IL-1 | interleukin-1 |
| IL-6 | interleukin-6 |
| JAK | Janus kinase |
| lncRNA | long noncoding RNA |
| LAG 3 | lymphocyte activation gene 3 |
| MET | mesenchymal-to-epithelial transition |
| MDSC | myeloid-derived suppressor cell |
| NK | natural killer |
| NGS | next-generation sequencing |
| ncRNA | noncoding RNA |
| OATP1B3 | organic anion transporter |
| ORR | overall response rate |
| OS | overall survival |
| P-gp | P-glycoprotein |
| PD-L1 | programmed cell death ligand 1 |
| PD-1 | programmed cell death protein-1 |
| PFS | progression-free survival |
| ROS | reactive oxygen species |
| Treg | regulatory T cell |
| STAT3 | signal transducer and activator of transcription 3 |
| SD | stable disease |
| TIM-3 | T-Cell Immunoglobulin and Mucin Domain 3 |
| TIGIT | T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif |
| TLS | tertiary lymphoid structure formation |
| 3D | three-dimensional |
| TACE | transarterial chemoembolization |
| TGF-β | transforming growth factor-beta |
| TTP | time to progression |
| TME | tumour microenvironment |
| TAM | tumour-associated macrophage |
| TIL | tumour-infiltrating lymphocyte |
| TKI | tyrosine kinase inhibitor |
| VISTA | V domain immunoglobulin suppressor of T-cell activation |
| VEGF | vascular endothelial growth factor |
| VEGFR | vascular endothelial growth factor receptor |